Labcorp Holdings Inc. announced the launch of an AI‑powered real‑world data platform on April 14, 2026, in partnership with Amazon Web Services and Datavant. The platform aggregates de‑identified, privacy‑protected healthcare data and applies advanced AI models to deliver insights in minutes that previously required months of data mining.
The new solution leverages Labcorp’s extensive blood‑based biomarker testing portfolio and its experience in neurology diagnostics. By providing rapid cohort identification, disease progression tracking, and treatment effectiveness measurement, the platform is designed to shorten clinical‑trial timelines and improve patient recruitment for Alzheimer’s drug development.
Labcorp’s move into AI‑driven data analytics expands its specialty testing moat and positions the company to capture a growing market for real‑world evidence in drug development. The platform is currently in its initial validation phase, expected to complete in spring 2026, with plans to expand to other disease areas later that year.
Bola Oyegunwa, Ph.D., Labcorp’s EVP and Chief Information and Technology Officer, said the platform “represents a powerful acceleration in Alzheimer’s research. By combining AI, advanced analytics and the scale of Labcorp’s diagnostic data, we’re redefining what’s possible—compressing months of manual data preparation into minutes.” Dr. Rowland Illing, Chief Medical Officer and Director of Healthcare and Life Sciences at AWS, noted that the collaboration “shows how AI can help reduce the time from hypothesis to actionable insight from months to minutes, potentially shaving years off the drug development process.”
The platform’s launch comes against a backdrop of 7.2 million Americans living with Alzheimer’s and annual U.S. care costs exceeding $380 billion. Labcorp’s Q4 2025 results—revenue of $3.52 billion and adjusted EPS of $4.07—highlight the company’s financial strength to support this investment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.